Collapsing focal segmental glomerulosclerosis progression to kidney failure following combination therapy with pembrolizumab and enfortumab vedotin: a case report
Background Pembrolizumab (PB), a PD-1 immune checkpoint inhibitor, and enfortumab vedotin (EV), a Nectin-4 targeting antibody-drug conjugate delivering the microtubule-disrupting payload MMAE, represent the current standard of care for advanced urothelial carcinoma. While PB-associated glomerulopathy is a recognized rare complication, collapsing glomerulopathy with nephrotic-range proteinuria developing approximately five weeks after starting combination EV and PB, along with subsequent progression to kidney failure in a patient with advanced pre-existing chronic kidney disease (CKD) to our knowledge, has not been previously described. Case presentation A 76-year-old male with high-grade urothelial carcinoma and baseline CKD G4 (eGFR 25 mL/min/1.73 m 2 , creatinine 2.5 mg/dL, proteinuria 2.1 g/24 h), attributed to diabetes, hypertension, and prior cisplatin-based chemotherapy, was started on PB 200 mg IV and EV 1 mg/kg IV on a 21-day cycle. Approximately five weeks after starting therapy, he developed AKI presenting with a creatinine of 3.1 mg/dL, eGFR of 20 mL/min/1.73 m 2 , and nephrotic-range proteinuria of 13.1 g/24 hours. Both agents were discontinued, and empiric corticosteroids were given. Kidney biopsy then showed collapsing focal segmental glomerulosclerosis (cFSGS) in 20% of glomeruli, with 53% global glomerulosclerosis and 70% interstitial fibrosis and tubular atrophy. Kidney function did not improve with corticosteroids or subsequent rituximab. Eleven months after starting therapy, he required hemodialysis (creatinine 8.4 mg/dL, eGFR 6 mL/min/1.73 m²) and remains dialysis-dependent. Discussion/conclusion This case highlights three key teaching points. First, advanced pre-existing CKD may increase the risk of irreversible progression after cFSGS following ADC-immunotherapy, underscoring the need for baseline nephrology evaluation in this population. Second, the hypothesized interaction between pembrolizumab-associated podocyte dedifferentiation and MMAE-mediated cytotoxicity could help explain why this combination may be hazardous to a compromised kidney. This hypothesis, together with the possibility of an ADC payload class effect, warrants investigation as ADC-immunotherapy regimens are more widely adopted. Third, once advanced interstitial fibrosis is established, immunosuppressive salvage is unlikely to alter the trajectory, and its toxicity must be weighed against a low probability of benefit.
Authors
- Caroline Gee
- Ramy Magdy Hanna (ORCID: https://orcid.org/0000-0003-1807-8909)
- Johnathan Zuckerman
- George Hitti
Institutions
- University of California, Los Angeles (US)
- University of California, Irvine (US)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s12882-026-05519-3
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of California, Irvine